ACM
RGNX icon

ACT Capital Management’s Regenxbio RGNX Stock Holding History

ACT Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$809K Buy
67,500
+11,500
+21% +$95.4K 0.53% 31
2026
Q1 		$469K Sell
56,000
-26,500
-32% -$278K 0.37% 35
2025
Q4 		$1.19M Buy
+82,500
New +$1.03M 0.96% 23

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

ACT Capital Management's RGNX Position: Q2 2026 in Review

ACT Capital Management increased its Regenxbio (RGNX) stake by 21% in Q2 2026, buying an estimated $95.4K and bringing the position to 67,500 shares worth $809K. The position accounts for 0.53% of the portfolio, ranked #31.

ACT Capital Management first reported a position in RGNX in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.19M in Q4 2025. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

  • ACT Capital Management held 67,500 shares of Regenxbio worth $809K as of Q2 2026.
  • ACT Capital Management bought 11,500 Regenxbio shares in Q2 2026, an estimated $95.4K.
  • Regenxbio made up 0.53% of ACT Capital Management's portfolio in Q2 2026, its #31 holding.
  • ACT Capital Management first reported a position in Regenxbio in Q4 2025 and has held it in 3 quarters since.
  • ACT Capital Management's Regenxbio position peaked at $1.19M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.